Latest news
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:30:00 GMTSarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - natlawreview.comnatlawreview.com · Mon, 10 Aug 2026 11:17:06 GMTSilence Therapeutics Reports Second Quarter 2026 Financial and Business Results - Business WireBusiness Wire · Mon, 10 Aug 2026 11:15:00 GMTSilence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera - Business WireBusiness Wire · Sun, 09 Aug 2026 21:00:00 GMT